<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00276471</url>
  </required_header>
  <id_info>
    <org_study_id>MC PT TAN2005-013</org_study_id>
    <nct_id>NCT00276471</nct_id>
  </id_info>
  <brief_title>Evaluation of the Tantalus System in Type 2 Diabetic Subjects</brief_title>
  <official_title>Evaluation of the Tantalus System in Type 2 Diabetic Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MetaCure Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MetaCure Limited</source>
  <brief_summary>
    <textblock>
      Metacure MC PT TAN2005-013 feasibility study is a prospective, multi-center, study to&#xD;
      evaluate the safety and functionality of the TANTALUS System, in the treatment of obese T2DM&#xD;
      patients, and to assess the effect of GCT ( Glycemic Control Treatment )on weight loss and&#xD;
      glycemic control.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the of device and/or procedure related adverse events</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of blood chemistry, hematology and urinalysis</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Ability to record electrical activity from the stomach</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Ability to communicate between patient wand and the device.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Significant decrease in the HbA1c values between baseline and end-of-treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in the required medications due to improved glycemia.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Significant reduction in weight loss between baseline and end-of-treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in co-morbid parameters</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Obesity</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implantable pulse generator and electrodes</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  T2DM subjects inadequately controlled on a maximum of three oral agents&#xD;
&#xD;
          -  Subjects with HbA1c between 7 and 9%&#xD;
&#xD;
          -  Subjects with FBG between 120 and 200 mg/dL&#xD;
&#xD;
          -  Subjects who are 21-60 years old&#xD;
&#xD;
          -  Women with childbearing potential (i.e. not post-menopausal or surgically sterilized)&#xD;
             must agree to use adequate birth control methods and must agree not to conceive for at&#xD;
             least 20 weeks&#xD;
&#xD;
          -  Subjects with Body Mass Index (BMI) between 30-38 (inclusive)&#xD;
&#xD;
          -  Subjects with waist circumference &gt;94 cm (males) and &gt;80 cm (females)&#xD;
&#xD;
          -  Subjects on stable medication program for at least three months with any oral&#xD;
             medication program&#xD;
&#xD;
          -  Subjects who are compliant, willing and able to participate in the follow-up visits&#xD;
             for the study duration of approximately 26 weeks&#xD;
&#xD;
          -  Alert, mentally competent, and able to understand and comply with the requirements of&#xD;
             the clinical trial, and be personally motivated to abide by the requirements and&#xD;
             restrictions of the clinical trial.&#xD;
&#xD;
          -  Able to provide voluntary informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects at high risk of general anesthesia or surgery&#xD;
&#xD;
          -  Subjects with prior pancreatitis&#xD;
&#xD;
          -  Subjects with chronic hepatitis&#xD;
&#xD;
          -  Subjects with elevated serum creatinine&#xD;
&#xD;
          -  Subjects with proliferative diabetic retinopathy&#xD;
&#xD;
          -  Subjects with gastroparesis or intestinal pseudo-obstruction&#xD;
&#xD;
          -  Subjects with motility disorders of the GI tract&#xD;
&#xD;
          -  Subjects who are receiving medications known to affect gastric motility&#xD;
&#xD;
          -  Subjects with a past or present psychiatric condition that may impair his or her&#xD;
             ability to comply with the study procedures&#xD;
&#xD;
          -  Subjects who are pregnant (proven by positive hCG), or lactating&#xD;
&#xD;
          -  Subjects who have had prior bariatric surgery&#xD;
&#xD;
          -  Subjects with a history of peptic ulcer disease&#xD;
&#xD;
          -  Subjects who have used another investigational device or agent in the 30 days prior to&#xD;
             implant or are participating in any other clinical study&#xD;
&#xD;
          -  Subjects with any new medical problem diagnosed or the worsening of an existing&#xD;
             medical problem during the baseline evaluation period&#xD;
&#xD;
          -  Subjects with a life-threatening co-morbidity or life expectancy of less than one year&#xD;
&#xD;
          -  Subjects with myocardial infarction or one or more episodes of unstable angina within&#xD;
             6 months prior to enrollment&#xD;
&#xD;
          -  Subjects with a history of malignant disease&#xD;
&#xD;
          -  Subjects who are currently on chemotherapy treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernhard Ludvik, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Allgemeinen Krankenhauses der Stadt Wein AkH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allgemeinen Krankenhauses der Stadt Wein AkH</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <study_first_submitted>January 12, 2006</study_first_submitted>
  <study_first_submitted_qc>January 12, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2006</study_first_posted>
  <last_update_submitted>January 31, 2012</last_update_submitted>
  <last_update_submitted_qc>January 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2012</last_update_posted>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

